natgillin/translations-raw huggingface dataset:
PHARMACEUTICAL FORM AND CONTENTS 250 ml oral solution 
OBLIK I SADRŽAJ 250 ml oralne otopine
ml of oral solution (three times/day) 
ml oralne otopine (tri puta/dan)
Sixty-one patients with cardiac iron overload, previously treated with deferoxamine, were randomized to continue deferoxamine (average dose 43 mg/kg/day; N=31) or to switch to Ferriprox (average dose 92 mg/kg/day N=29). 
Šezdeset jedan bolesnik s preopterećenjem srca željezom, prethodno liječenih deferoksaminom, randomizirano je u skupinu koja je nastavila primati deferoksamin (prosječna doza 43 mg/kg/dan; n=31), odnosno u skupinu koja se prebacila na Ferriprox (prosječna doza 92 mg/kg/dan n=29).
Ferriprox 1000 mg film-coated tablets EU/1/99/108/004 
Ferriprox 1000 mg filmom obložene tablete EU/1/99/108/004
To monitor for neutropenia, your doctor will ask you to have a blood test (to check your white blood cell count) performed regularly, as frequently as every week, while you are being treated with Ferriprox. 
Radi nadziranja neutropenije, Vaš liječnik će od Vas tijekom liječenja Ferriproxom tražiti da redovito radite krvne pretrage (kako bi se provjerio broj bijelih krvnih stanica).
Ferriprox is used to treat iron overload caused by frequent blood transfusions in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. 
Ferriprox se koristi se za liječenje preopterećenja željezom uzrokovanog čestim transfuzijama krvi u bolesnika s talasemijom major kada je trenutna kelacijska terapija kontraindicirana ili neodgovarajuća.
Following a dose of 25 mg/kg, lower peak serum concentrations have been detected in patients in the fed state (85 µmol/l) than in the fasting state (126 µmol/l), although there was no decrease in the amount of deferiprone absorbed when it was given with food. 
(85 µmol/l) nego u onih natašte (126 µmol/l), premda nije bilo smanjenja u količini apsorbiranog deferiprona ako se davao s hranom.
Myocardial MRI T2* values of less than 20 ms represent iron overload in the heart. 
vrijednosti miokarda manje od 20 ms predstavljaju preopterećenje srca željezom.
− if you have a history of agranulocytosis (very low white blood cell (neutrophil) count). 
− ako ste u povijesti bolesti imali agranulocitozu (vrlo niski broj bijelih krvnih stanica (neutrofila)).
To obtain a dose of about 75 mg/kg/day, use the volume of oral solution suggested in the following table for the body weight of the patient. 
Za određivanje doze od oko 75 mg/kg/dan, koristiti preporučeni volumen oralne otopine naveden u sljedećoj tablici prema tjelesnoj težini bolesnika.
500 ml oral solution 
500 ml oralne otopine
Based on the results of this study, no adjustment of the Ferriprox dosage regimen is required in patients with impaired renal function. 
Na temelju rezultata ovog ispitivanja, nije potrebna prilagodba režima doziranja lijeka Ferriprox u bolesnika s oštećenjem funkcije bubrega.
Clear, reddish orange-coloured liquid. 
Bistra, crvenkasto narančasta tekućina.
After one year of study therapy, patients on concurrent chelation therapy had experienced a significantly greater reduction in serum ferritin (1574 µg/l to 598 µg/l with concurrent therapy vs. 1379 µg/l to 1146 µg/l with deferoxamine monotherapy, p<0.001), significantly greater reduction in myocardial iron overload, as assessed by an increase in MRI T2* (11.7 ms to 17.7 ms with concurrent therapy vs. 12.4 ms to 15.7 ms with deferoxamine monotherapy, p=0.02) and significantly greater reduction in liver iron concentration, also assessed by an increase in MRI T2* (4.9 ms to 10.7 ms with concurrent therapy vs. 4.2 ms to 5.0 ms with deferoxamine monotherapy, p< 0.001). 
Nakon jedne godine terapije u ispitivanju, bolesnici na istodobnoj kelacijskoj terapiji doživjeli su značajno veće smanjenje serumskog feritina (1574 µg/l do 598 µg/l s istodobnom terapijom naspram 1379 µg/l do 1146 µg/l s monoterapijom deferoksaminom, p<0,001), značajno veće smanjenje u opterećenju miokarda željezom, što je procijenjeno povećanjem u MR T2* (11,7 ms do 17,7 ms s istodobnom terapijom naspram 12,4 ms do 15,7 ms s monoterapijom deferoksaminom,
Based on the results of this study, no adjustment of the Ferriprox dosage regimen is required in patients with mildly or moderately impaired hepatic function. 
Na temelju rezultata ovog ispitivanja, nije potrebna prilagodba režima doziranja lijeka Ferriprox u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre.
- Due to the unknown mechanism of deferiprone-induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 4.5). 
- Zbog nepoznatog mehanizma nastanka neutropenije izazvane deferipronom, bolesnici ne smiju uzimati lijekove za koje je poznato da su povezani s neutropenijom ili lijekove koji mogu uzrokovati agranulocitozu (vidjeti dio 4.5).
Subjects were categorized into 4 groups based on estimated glomerular filtration rate (eGFR): healthy volunteers (eGFR ≥ 90 mL/min/1.73m2), mild renal impairment (eGFR 60-89 mL/min/1.73m2), moderate renal impairment (eGFR 30-59 mL/min/1.73m2), and severe renal impairment (eGFR 15-29 mL/min/1.73m2). 
Ispitanici su na temelju procijenjene brzine glomerularne filtracije (eGFR) bili podijeljeni u 4 skupine: zdravi dobrovoljci (eGFR ≥ 90 ml/min/1,73m2), ispitanici s blagim oštećenjem funkcije bubrega (eGFR 60-89 ml/min/1,73m2), ispitanici s umjerenim oštećenjem funkcije bubrega (eGFR 30-59 ml/min/1,73m2) i ispitanici s teškim oštećenjem funkcije bubrega (eGFR 15-29 ml/min/1,73m2).
Dose adjustment is not required in patients with mildly or moderately impaired hepatic function (see section 5.2). 
Nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre (vidjeti dio 5.2).
The other ingredients are: purified water; hydroxyethylcellulose; glycerol (E422); hydrochloric acid, concentrated (for pH adjustment); artificial cherry flavour; peppermint oil; Sunset Yellow (E110); sucralose (E955). 
koncentrirana (za prilagodbu pH); umjetna aroma trešnje; ulje paprene metvice; Sunset Yellow (E110); sukraloza (E955).
Report immediately to your doctor any symptoms of infection such as: fever, sore throat or flu-like symptoms. 
Odmah prijavite svom liječniku bilo koje simptome infekcije poput: vrućice, grlobolje ili simptoma nalik gripi.
Pack size of 50 tablets. 
Veličina pakiranja: 50 tableta.
• To increase patient awareness of the importance of regular monitoring of the neutrophil count during treatment with deferiprone 
• podizanje razine osviještenosti bolesnika o važnosti redovitog praćenja broja neutrofila tijekom liječenja deferipronom
The most serious adverse reaction reported in clinical trials with deferiprone is agranulocytosis (neutrophils <0.5x109/l), with an incidence of 1.1% (0.6 cases per 100 patient-years of treatment) (see section 4.4). 
Najozbiljnija nuspojava prijavljena u kliničkim ispitivanjima s deferipronom je agranulocitoza (neutrofili <0,5x109/l), s incidencijom od 1,1% (0,6 slučajeva na 100 bolesnika-godina liječenja)
Do not use this medicine after the expiry date which is stated on the carton and the label after EXP. Do not store above 30ºC. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i naljepnici iza oznake „EXP“.
Suggested management of cases of neutropenia is outlined below. 
Preporučeno liječenje slučajeva neutropenije navedeno je u nastavku.
The most serious side effect of Ferriprox is a very low white blood cell (neutrophil) count. 
Najozbiljnija nuspojava Ferriproxa je vrlo nizak broj bijelih krvnih stanica (neutrofila).
Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. 
Monoterapija Ferriproxom indicirana je za liječenje preopterećenja željezom u bolesnika s talasemijom major kada je trenutna kelacijska terapija kontraindicirana ili neodgovarajuća.
Name and address of the manufacturers responsible for batch release Eurofins PROXY Laboratories B.V. 
Proizvođač odgovoran za puštanje serije lijeka u promet: Eurofins PROXY Laboratories B.V.
Do not take aluminium-based antacids at the same time as taking Ferriprox. 
Nemojte uzimati antacide na bazi aluminija za vrijeme liječenja s lijekom Ferriprox.
Do not take Ferriprox if you are pregnant or if you are trying to become pregnant. 
ZA ŽENE REPRODUKTIVNE DOBI Nemojte uzimati Ferriprox ako ste trudni ili nastojite zatrudnjeti.
An open-label, non-randomized, parallel group clinical study was conducted to evaluate the effect of impaired renal function on the safety, tolerability, and pharmacokinetics of a single 33 mg/kg oral dose of Ferriprox. 
Provedeno je otvoreno, nerandomizirano kliničko ispitivanje s paralelnim skupinama kako bi se procijenio učinak oštećenja funkcije bubrega na sigurnost, podnošljivost i farmakokinetiku jedne peroralne doze Ferriproxa od 33 mg/kg.
What Ferriprox contains The active substance is deferiprone. 
Što Ferripox sadrži Djelatna tvar je deferipron.
- History of recurrent episodes of neutropenia. 
- Rekurentne epizode neutropenije u anamnezi.
Regardless of the degree of renal impairment, the majority of the dose of Ferriprox was excreted in the urine over the first 24 hours as deferiprone 3-O-glucuronide. 
Bez obzira na stupanj oštećenja bubrega, većina doze Ferriproxa izlučuje se putem urina tijekom prvih
Neurological disorders (such as tremors, walking disorders, double vision, involuntary muscle contractions, problems with movement coordination) have been reported in children who had been voluntarily prescribed more than double the maximum recommended dose of 100 mg/kg/day for several years and have also been observed in children with standard doses of deferiprone. 
Neurološki poremećaji (kao što je nevoljno drhtanje, poremećaji hodanja, dvoslika, nevoljno grčenje mišića, problemi s koordinacijom pokreta) prijavljeni su kod djece kojoj je dobrovoljno propisivana više od dvostruko puta veća doza od maksimalno preporučene doze od 100 mg/kg/dan tijekom nekoliko godina no opaženi su i kod standardnih doza deferiprona u djece.
Pack size of 100 tablets. 
Veličina pakiranja: 100 tableta.
- Breast-feeding (see section 4.6). 
- Dojenje (vidjeti dio 4.6).
You must use effective contraception while you are taking Ferriprox. 
Dok uzimate Ferriprox morate koristiti učinkovitu kontracepciju.
Tel: + 385 1 4874 500 
Providens d.o.o. Tel: + 385 1 4874 500
Each 500 mg tablet contains 500 mg deferiprone. 
Svaka tableta od 500 mg sadrži 500 mg deferiprona.
In the case of iron-induced heart failure, Ferriprox at 75-100 mg/kg/day should be added to deferoxamine therapy. 
U slučaju zatajenja srca induciranog željezom, potrebno je terapiji s deferoksaminom dodati Ferriprox od 75-100 mg/kg/dan.
The other ingredients are: Tablet core: Microcrystalline cellulose, Magnesium stearate, Colloidal silicon dioxide. 
Pomoćne tvari su: Jezgra tablete: mikrokristalična celuloza, magnezijev stearat, koloidni silicijev dioksid.
Important Safety Reminders for Patients taking Ferriprox (deferiprone) Prescribing doctor: _________________ Phone No: ________________________ 
Važni sigurnosni podsjetnik za bolesnike koji uzimaju Ferriprox (deferipron)
Abdominal Pain Vomiting 
Poremećaji probavnog sustava mučnina bol u abdomenu povraćanje proljev
The patient's absolute neutrophil count (ANC) should be monitored every week during the first year of therapy. 
Tijekom prve godine liječenja, bolesniku se apsolutni broj neutrofila (ABN) mora kontrolirati svaki tjedan.
Coating: Hypromellose, hydroxypropyl cellulose, macrogol, titanium dioxide. 
Ovojnica: hipromeloza, hidroksipropilceluloza, makrogol, titanijev dioksid.
Renal and hepatic function should be monitored in these patient populations during deferiprone therapy. 
Tijekom terapije deferipronom potrebno je pratiti funkciju bubrega i jetre u ovoj populaciji bolesnika.
However, neurological disorders (such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, hand movements and axial hypotonia) have been observed in children who had been voluntarily prescribed more than 2.5 times the maximum recommended dose of 100 mg/kg/day for several years. 
Ipak, neurološki poremećaji (poput cerebelarnih simptoma, diplopije, lateralnog nistagmusa, psihomotornog usporavanja, nevoljnih pokreta ruku i aksijalne hipotonije) opaženi su u djece kojoj je dobrovoljno propisivana više od 2,5 puta veća doza od maksimalno preporučene doze od 100 mg/kg/dan tijekom nekoliko godina.
EXP After first opening use within 50 days. 
EXP Nakon prvog otvaranja upotrijebiti unutar 50 dana.
Do not take Ferriprox 
Nemojte uzimati Ferriprox:
MARKETING AUTHORISATION NUMBER Ferriprox 500 mg film-coated tablets EU/1/99/108/001 
Ferriprox 500 mg filmom obložene tablete EU/1/99/108/001
Due to the unknown mechanism of deferiprone-induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 
Zbog nepoznatog mehanizma nastanka neutropenije izazvane deferipronom, bolesnici ne smiju uzimati lijekove za koje se zna da su povezani s neutropenijom ili lijekove koji mogu uzrokovati agranulocitozu (vidjeti dio 4.3).
After first opening use within 50 days. 
Nakon prvog otvaranja upotrijebiti unutar 50 dana.
After first opening use within 35 days. 
Nakon prvog otvaranja upotrijebiti unutar 35 dana.
EXP After first opening use within 35 days. 
EXP Nakon prvog otvaranja upotrijebiti unutar 35 dana.
Coating: Hypromellose, Macrogol, Titanium dioxide. 
Ovojnica: hipromeloza, makrogol, titanijev dioksid.
Neurological disorders (such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, hand movements and axial hypotonia) have been observed in children who had been voluntarily prescribed more than 2.5 times the maximum recommended dose of 100 mg/kg/day for several years. 
Neurološki poremećaji (poput cerebelarnih simptoma, diplopije, lateralnog nistagmusa, psihomotornog usporavanja, nevoljnih pokreta ruku i aksijalne hipotonije) opaženi su u djece kojoj je dobrovoljno propisivana više od 2,5 puta veća doza od maksimalno preporučene doze od 100 mg/kg/dan tijekom nekoliko godina.
How to take Ferriprox 
Kako uzimati Ferriprox
Tablet core: Methylcellulose, crospovidone, magnesium stearate. 
Pomoćne tvari su: Jezgra tablete: metilceluloza, krospovidon, magnezijev stearat.
Ferriprox 1000 mg film-coated tablets Each tablet contains 1000 mg deferiprone. 
Ferriprox 1000 mg filmom obložene tablete Svaka tableta sadrži 1000 mg deferiprona.
LIST OF EXCIPIENTS Contains Sunset Yellow (E110); see leaflet for further information. 
Sadrži boju Sunset Yellow (E110); za dodatne informacije vidjeti Uputu o lijeku.
Each 1000 mg tablet contains 1000 mg deferiprone. 
Svaka tableta od 1000 mg sadrži 1000 mg deferiprona.
Metabolism and nutrition disorders 
Poremećaji metabolizma i prehrane povećan apetit
INFORMATION IN BRAILLE Ferriprox 100 mg/ml 
16. PODACI NA BRAILLEOVOM PISMU Ferriprox 100 mg/ml
INFORMATION IN BRAILLE Ferriprox 1000 mg 
16. PODACI NA BRAILLEOVOM PISMU Ferriprox 1000 mg
Neutropenia/Agranulocytosis 
Neutropenija/agranulocitoza
Dose table for Ferriprox 1000 mg film-coated tablets Body weight (kg) 
Tablica doziranja za Ferriprox 1000 mg filmom obložene tablete Tjelesna težina (kg)
In thalassaemia patients there is an association between liver fibrosis and iron overload and/or hepatitis C. Special care must be taken to ensure that iron chelation in patients with hepatitis C is optimal. 
U bolesnika s talasemijom postoji povezanost između fibroze jetre i preopterećenja željezom i/ili hepatitisa C.
What Ferriprox looks like and contents of the pack Ferriprox oral solution is a clear, reddish orange coloured liquid. 
Ferriprox oralna otopina je bistra, crvenkasto narančasta tekućina.
Hypersensitivity reactions 
Poremećaji imunološkog sustava reakcije preosjetljivosti
Each ml of oral solution contains 100 mg deferiprone. 
Svaki ml oralne otopine sadrži 100 mg deferiprona.
- History of agranulocytosis. 
- Agranulocitoza u anamnezi.
The tablet is scored. 
Tableta ima razdjelnu crtu.
Each ml of oral solution contains 100 mg deferiprone (25 g deferiprone in 250 ml). 
Svaki ml oralne otopine sadrži 100 mg deferiprona (25 g deferiprona u 250 ml).
INFORMATION IN BRAILLE Ferriprox 500 mg 
16. PODACI NA BRAILLEOVOM PISMU Ferriprox 500 mg
Do not take Ferriprox if you are breast-feeding. 
Ne uzimajte Ferriprox ako dojite.
Sample body weights at 10 kg increments are listed. 
Prikazani su primjeri tjelesne težine s porastom za po 10 kg.
Caution must be exercised in patients with end stage renal disease or severe hepatic dysfunction. 
U bolesnika sa završnim stadijem bolesti bubrega ili teškim oštećenjem funkcije jetre potreban je oprez.
How to store Ferriprox 
Kako čuvati Ferriprox
Blood and lymphatic system disorders 
Poremećaji krvi i limfnog sustava neutropenija agranulocitoza
The tablets are scored and breakable in half. 
Tablete imaju razdjelnu crtu i mogu se podijeliti na jednake polovice.
The safety and pharmacokinetics of Ferriprox in patients with end stage renal disease is unknown. 
Sigurnost i farmakokinetika lijeka Ferriprox u bolesnika sa završnim stadijem bolesti bubrega nisu poznate.
SYSTEM ORGAN CLASS VERY COMMON 
KLASIFIKACIJA ORGANSKIH SUSTAVA
The levels normalised with oral zinc supplementation. 
Razine su se normalizirale peroralnim uzimanjem nadomjestaka cinka.
High density polyethylene (HDPE) bottle with a child resistant polypropylene cap and a desiccant. 
Boca od polietilena visoke gustoće (HDPE) sa polipropilenskim zatvaračem sigurnim za djecu i sredstvom za sušenje.
Do not take medicines known to cause neutropenia or agranulocytosis (see “Do not take Ferriprox”). 
Nemojte uzimati lijekove za koje se zna da uzrokuju neutropeniju ili agranulocitozu (pogledajte dio
− Attached to this leaflet you will find a patient/carer reminder card. You should detach, 
Pogledajte dio 4. − Uz ovu Uputu o lijeku naći ćete karticu s podsjetnikom za bolesnika/njegovatelja.
FOR WOMEN OF CHILD BEARING AGE 
I DOHVATA DJECE
Each ml of oral solution contains 100 mg deferiprone (50 g deferiprone in 500 ml). 
Svaki ml oralne otopine sadrži 100 mg deferiprona (50 g deferiprona u 500 ml).
Each ml of oral solution contains 100 mg deferiprone (25 g deferiprone in 250 ml and 50 g deferiprone in 500 ml). 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaki ml oralne otopine sadrži 100 mg deferiprona (25 g deferiprona u 250 ml i 50 g deferiprona u 500 ml).
FREQUENCY NOT KNOWN 
NEPOZNATA
The most serious adverse reaction reported in clinical trials with deferiprone was agranulocytosis, defined as an absolute neutrophil count less than 0.5 x 109/l, which occurred in approximately 1% of patients. 
definirana kao apsolutni broj neutrofila manji od 0,5 x 109/l, što se dogodilo kod otprilike 1% bolesnika.
The safety and pharmacokinetics of Ferriprox in patients with severe hepatic impairment is unknown. 
Sigurnost i farmakokinetika lijeka Ferriprox u bolesnika s teškim oštećenjem jetre nisu poznate.
MARKETING AUTHORISATION HOLDER Apotex B.V. 
Nositelj odobrenja za stavljanje lijeka u promet i proizvođač Nositelj odobrenja za stavljanje lijeka u promet: Apotex B.V.
NAME OF THE MEDICINAL PRODUCT Ferriprox 100 mg/ml oral solution 
NAZIV LIJEKA Ferriprox 100 mg/ml oralna otopina
NAME OF THE MEDICINAL PRODUCT Ferriprox 100 mg/ml oral solution deferiprone 
NAZIV LIJEKA Ferriprox 100 mg/ml oralna otopina deferipron
High density polyethylene (HDPE) bottle with a child resistant polypropylene cap. 
Boca od polietilena visoke gustoće (HDPE) sa polipropilenskim zatvaračem sigurnim za djecu.
Interruption of therapy with deferiprone should be considered if serum ferritin falls below 500 µg/l. 
Ako mjerenja feritina u serumu padnu ispod 500 µg/l treba razmotriti prekid treapije deferipironom.
QUALITATIVE AND QUANTITATIVE COMPOSITION Ferriprox 500 mg film-coated tablets Each tablet contains 500 mg deferiprone. 
Ferriprox 500 mg filmom obložene tablete Svaka tableta sadrži 500 mg deferiprona.
MARKETING AUTHORISATION NUMBER EU/1/99/108/002 
ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/99/108/002
The neutrophil count should be then monitored more frequently. 
Nakon toga broj neutrofila treba pratiti učestalije.
What Ferriprox looks like and contents of the pack Ferriprox 500 mg tablets are white to off-white, capsule-shaped, film-coated tablets imprinted “APO” bisect “500” on one side, plain on the other. 
Tablete Ferriproxa od 500 mg su bijele do bjelkaste filmom obložene tablete u obliku kapsula, s otisnutom oznakom „APO“ s jedne strane razdjelne crte i „500“ s druge strane na jednoj strani tablete, te bez oznaka s druge strane.
What Ferriprox looks like and contents of the pack Ferriprox 1000 mg tablets are white to off-white, capsule-shaped, film-coated tablets imprinted “APO” bisect “1000” on one side, plain on the other. 
Tablete Ferriproxa od 1000 mg su bijele do bjelkaste filmom obložene tablete u obliku kapsula, s otisnutom oznakom „APO“ s jedne strane razdjelne crte i „1000“ s druge na jednoj strani tablete, te bez oznaka s druge strane.
Tel: + 421-2-59 30 00 60 
Chiesi Slovakia s.r.o. Tel: + 421-2-59 30 00 60
NAME OF THE MEDICINAL PRODUCT Ferriprox 500 mg film-coated tablets Ferriprox 1000 mg film-coated tablets 
Ferriprox 500 mg filmom obložene tablete Ferriprox 1000 mg filmom obložene tablete
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: 
Proizvođač odgovoran za puštanje serije lijeka u promet:
Deferiprone must not be used by breast-feeding mothers. 
Žene koje doje ne smiju uzimati deferipron.
Ferriprox 1000 mg film-coated tablets 
Ferriprox 1000 mg filmom obložene tablete
White to off-white, capsule-shaped, film-coated tablets imprinted “APO” bisect “1000” on one side, plain on the other. 
Bijele do bjelkaste filmom obložene tablete oblika kapsule, s otisnutom oznakom „APO“ s jedne strane razdjelne crte i „1000“ s druge strane na jednoj strani tablete, te bez oznaka s druge strane.
Ferriprox 500 mg film-coated tablets 
Ferriprox 500 mg filmom obložene tablete
White to off-white, capsule-shaped, film-coated tablets imprinted “APO” bisect “500” on one side, plain on the other. 
Bijele do bjelkaste filmom obložene tablete oblika kapsule, s otisnutom oznakom „APO“ s jedne strane razdjelne crte i „500“ s druge strane na jednoj strani tablete, te bez oznaka s druge strane.
Hydrochloric acid, concentrated, for pH adjustment Artificial cherry flavour 
6.1 Popis pomoćnih tvari voda, pročišćena hidroksietilceluloza glicerol (E422) kloridna kiselina, koncentrirana, za prilagodbu pH
Nausea 
Plodnost
See tables below for recommended doses for body weights at 10 kg increments. 
Preporučene doze prema tjelesnoj težini, s porastom za po 10 kg, vidjeti u tablicama u nastavku.
Titanium dioxide 
Ovojnica hipromeloza makrogol titanijev dioksid
Ferriprox 1000 mg film-coated tablets deferiprone 
Ferriprox 1000 mg filmom obložene tablete deferipron
Discoloration of urine 
Promjena boje mokraće
Microcrystalline cellulose Magnesium stearate Colloidal silicon dioxide 
Ferriprox 500 mg filmom obložene tablete Jezgra tablete celuloza, mikrokristalična magnezijev stearat silicijev dioksid, koloidni
Ferriprox 500 mg film-coated tablets deferiprone 
Ferriprox 500 mg filmom obložene tablete deferipron
− if you are currently taking medicines known to cause neutropenia or agranulocytosis (see “Other medicines and Ferriprox”). 
(pogledajte dio „Drugi lijekovi i Ferriprox“).
Тел. 
Ltd.
Concurrent use of iron chelators is not recommended in patients whose serum ferritin falls below 500 µg/l due to the risk of excessive iron removal. 
Istodobna primjena kelatora željeza se ne preporučuje kod bolesnika čiji serumski feritin padne ispod
Tablet core 
Tablica doziranja
Neutropenia Agranulocytosis 
Prijavljivanje nuspojava
Dose table for Ferriprox 500 mg film-coated tablets 
Tablica doziranja za Ferriprox 500 mg filmom obložene tablete Tjelesna težina
MARKETING AUTHORISATION NUMBER(S) EU/1/99/108/004 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/99/108/004
Hydroxypropyl cellulose 
umjetna aroma trešnje ulje paprene metvice
MARKETING AUTHORISATION NUMBER(S) EU/1/99/108/001 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/99/108/001